Johnson JL - Search Results

1

Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.

Johnson JL, Downes JM, Obi CK, Asante NB. Johnson JL, et al. J Diabetes Sci Technol. 2017 May;11(3):618-622. doi: 10.1177/1932296816680830. Epub 2016 Nov 28. J Diabetes Sci Technol. 2017. PMID: 27898390 Free PMC article. Review.

2

Identifying opportunities to improve medication management in transitions of care.

Downes JM, O'Neal KS, Miller MJ, Johnson JL, Gildon BL, Weisz MA. Downes JM, et al. Among authors: johnson jl. Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S58-69. doi: 10.2146/ajhp150059. Am J Health Syst Pharm. 2015. PMID: 26272894

3

Barriers to Patient Use of Control Solution for Glucose Meters: Surveys of Patients, Pharmacists, and Providers in a Metropolitan Area.

Johnson JL, O'Neal KS, Pack CC, Carter SM. Johnson JL, et al. J Diabetes Sci Technol. 2017 May;11(3):553-557. doi: 10.1177/1932296816678427. Epub 2016 Nov 15. J Diabetes Sci Technol. 2017. PMID: 28745089 Free PMC article.

4

The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.

Matli MC, Wilson AB, Rappsilber LM, Sheffield FP, Farlow ML, Johnson JL. Matli MC, et al. Among authors: johnson jl. J Diabetes Sci Technol. 2023 Mar;17(2):490-494. doi: 10.1177/19322968211067511. Epub 2021 Dec 31. J Diabetes Sci Technol. 2023. PMID: 34971335 Free PMC article. Review.

5

An exploratory survey on the awareness and usage of clinical practice guidelines among clinical pharmacists.

Downes JM, Appeddu LA, Johnson JL, Haywood KS, James BJ, Wingard KD. Downes JM, et al. Among authors: johnson jl. Explor Res Clin Soc Pharm. 2021 Apr 21;2:100013. doi: 10.1016/j.rcsop.2021.100013. eCollection 2021 Jun. Explor Res Clin Soc Pharm. 2021. PMID: 35481123 Free PMC article.

6

Nontraditional Considerations With Insulin Needle Length Selection.

O'Neal KS, Johnson J, Swar S. O'Neal KS, et al. Diabetes Spectr. 2015 Nov;28(4):264-7. doi: 10.2337/diaspect.28.4.264. Diabetes Spectr. 2015. PMID: 26600728 Free PMC article.

7

Management of a prediabetes case with the DPP-4 inhibitor sitagliptin.

Johnson JL, O'Neal KS, Pack CC, Kim MK. Johnson JL, et al. Ann Pharmacother. 2014 Jun;48(6):811-5. doi: 10.1177/1060028014528681. Epub 2014 Mar 27. Ann Pharmacother. 2014. PMID: 24676549

8

Recognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults.

O'Neal KS, Johnson JL, Panak RL. O'Neal KS, et al. Among authors: johnson jl. Diabetes Spectr. 2016 Nov;29(4):249-252. doi: 10.2337/ds15-0047. Diabetes Spectr. 2016. PMID: 27899877 Free PMC article. No abstract available.

9

The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes.

Inman TR, Plyushko E, Austin NP, Johnson JL. Inman TR, et al. Among authors: johnson jl. Ther Adv Endocrinol Metab. 2018 May;9(5):151-155. doi: 10.1177/2042018818763698. Epub 2018 Apr 23. Ther Adv Endocrinol Metab. 2018. PMID: 29796245 Free PMC article. Review.

10

Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin.

Fanshier AV, Crews BK, Garrett MC, Johnson JL. Fanshier AV, et al. Among authors: johnson jl. Clin Diabetes. 2023 Summer;41(3):367-377. doi: 10.2337/cd22-0060. Epub 2023 Mar 2. Clin Diabetes. 2023. PMID: 37456095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,677 results

Search Page